Companies such as Novo Nordisk (NVO), which makes Ozempic, and Eli Lilly (LLY), which sells Mounjaro, have raised the list prices on 775 name drugs in the first half of January, Jennifer Calfas of The Wall Street Journal reports, citing an analysis done by 46brooklyn Research. The prices of their medicine were raised by a median of 4.5%, though some were raised by around 10% or higher, according to the research group.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
See Insiders’ Hot Stocks on TipRanks >>
Read More on NVO:
- Novo Nordisk price target raised to DKK 800 from DKK 730 at Morgan Stanley
- Novo Nordisk upgraded to Neutral from Sell at UBS
- Analysts and Technical Indicators Agree: These 3 Stocks Are “Strong Buys” – 1/15/2024
- Regeneron to test Wegovy drug combos to protect muscle mass, Bloomberg says
- Novo Nordisk price target raised to DKK 850 from DKK 775 at Deutsche Bank